Bladder cancer (English Wikipedia)

"Diet, Nutrition, Physical Activity and Bladder Cancer" (PDF). World Cancer Research Fund, American Institute for Cancer Research. 2018. p. 20. Retrieved 17 October 2024.

appliedradiationoncology.com (Global: low place; English: low place)

Schmitt LG, Amarnath SR (1 September 2023). "Late Effects of Pelvic Radiation Therapy in the Female Patient: A Comprehensive Review". Applied Radiation Oncology. 2023 (3): 13–24. doi:10.37549/ARO-D-23-00016. Retrieved 16 October 2024.

bcan.org (Global: low place; English: low place)

"Home". Bladder Cancer Advocacy Network. Retrieved 12 March 2025.

cancer.gov (Global: 1,906^th place; English: 1,649^th place)

"Treatment of Bladder Cancer by Stage". www.cancer.gov. National Cancer Institute. 12 September 2024. Retrieved 29 January 2025. Treatment of Bladder Cancer by Stage was originally published by the National Cancer Institute.
"Immunotherapy Side Effects". www.cancer.gov. National Cancer Institute. 16 February 2023. Retrieved 29 January 2025. Immunotherapy Side Effects was originally published by the National Cancer Institute.
"Targeted Therapy to Treat Cancer". www.cancer.gov. National Cancer Institute. 31 May 2022. Retrieved 29 January 2025. Targeted Therapy to Treat Cancer was originally published by the National Cancer Institute.
"Treatment of Bladder Cancer by Stage - NCI". www.cancer.gov. 16 February 2023. Retrieved 20 July 2026.

cancer.org (Global: 4,631^st place; English: 3,828^th place)

"Tests for Bladder Cancer". American Cancer Society. 12 March 2024. Retrieved 8 August 2024.
"Treatment of Bladder Cancer, Based on Stage and Other Factors". American Cancer Society. 1 May 2024.
"Treatment of Bladder Cancer, Based on the Stage and Other Factors". www.cancer.org. American Cancer Society. 1 May 2024. Retrieved 11 January 2025.
"Living as a Bladder Cancer Survivor". American Cancer Society. 12 March 2024. Retrieved 15 November 2024.
"Chemotherapy for Cervical Cancer". www.cancer.org. American Cancer Society. 28 June 2024. Retrieved 24 October 2024.
"Immunotherapy for Bladder Cancer". www.cancer.org. American Cancer Society. 30 October 2024. Retrieved 12 January 2025.
"What Causes Bladder Cancer?". American Cancer Society. 12 March 2024. Retrieved 2 July 2024.
"Bladder Cancer Risk Factors". www.cancer.org. American Cancer Society. 12 March 2024. Retrieved 12 January 2025.

cancerresearchuk.org (Global: 9,972^nd place; English: 7,596^th place)

"Symptoms of Metastatic Bladder Cancer". Cancer Research UK. 14 March 2023. Retrieved 11 November 2024.
"Types of Bladder Cancer". Cancer Research UK. 22 September 2024. Retrieved 26 August 2024.
"Stages of Bladder Cancer". Cancer Research UK. 22 September 2022. Retrieved 29 August 2024.
"Surgery to Remove the Bladder (Cystectomy)". Cancer Research UK. 11 November 2022. Retrieved 16 September 2024.
"Continent Urinary Diversion (Internal Pouch)". Cancer Research UK. 24 November 2022. Retrieved 17 September 2024.
"Bladder Reconstruction (Neobladder)". Cancer Research UK. 25 November 2024. Retrieved 17 September 2024.
"How Does Cancer Start". Cancer Research UK. 6 October 2023. Retrieved 24 October 2024.
"Cancer Research UK". Cancer Research UK. Retrieved 12 March 2025.

doi.org (Global: 2^nd place; English: 2^nd place)

Lenis, Lec & Chamie 2020, p. 1981. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Ahmadi, Duddalwar & Daneshmand 2021, pp. 532–533. Ahmadi H, Duddalwar V, Daneshmand S (June 2021). "Diagnosis and Staging of Bladder Cancer". Hematol Oncol Clin North Am. 35 (3): 531–541. doi:10.1016/j.hoc.2021.02.004. PMID 33958149.
Lenis, Lec & Chamie 2020, p. 1982. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Lenis, Lec & Chamie 2020, p. 1980. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Ng CP, Light A, Eleftheriou C, Hug O, Richardson E, Gill-Taylor T, et al. (July 2025). "Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study". BJUI Compass. 6 (7) e70052. doi:10.1002/bco2.70052. ISSN 2688-4526. PMC 12270553. PMID 40678112.
Srour MD, Mohamed A, Mathur S (October 2025). "Comparative Efficacy of Transurethral Laser Ablation Versus Conventional Methods in the Management of Recurrent Non-Muscle-Invasive Bladder Tumours". Cureus. 17 (10) e94455. doi:10.7759/cureus.94455. ISSN 2168-8184. PMC 12612793. PMID 41246593.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection-A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection—A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Xu J, Wang C, Ouyang J, Sun J, Hu C (2020). "Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review". Urologia Internationalis. 104 (9–10): 810–823. doi:10.1159/000506655. ISSN 1423-0399. PMID 32460292.
Teoh et al. 2022, p. 280. Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M (May 2022). "Recurrence mechanisms of non-muscle-invasive bladder cancer – a clinical perspective". Nat Rev Urol. 19 (5): 280–294. doi:10.1038/s41585-022-00578-1. PMID 35361927.
Compérat et al. 2022, pp. 1717–1718. Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. (November 2022). "Current best practice for bladder cancer: a narrative review of diagnostics and treatments". Lancet. 400 (10364): 1712–1721. doi:10.1016/S0140-6736(22)01188-6. PMID 36174585.
Lenis, Lec & Chamie 2020, p. 1986. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Schmitt LG, Amarnath SR (1 September 2023). "Late Effects of Pelvic Radiation Therapy in the Female Patient: A Comprehensive Review". Applied Radiation Oncology. 2023 (3): 13–24. doi:10.37549/ARO-D-23-00016. Retrieved 16 October 2024.
Huh JW, Tanksley J, Chino J, Willett CG, Dewhirst MW (1 July 2020). "Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators". Clinical Cancer Research. 26 (13): 3079–3090. doi:10.1158/1078-0432.CCR-19-2744. ISSN 1078-0432. PMID 32098770. Retrieved 24 October 2024.
Chen X, Li Y, Huang J, Zhang Q, Tan C, Liu Y, et al. (6 November 2024). "Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in bladder urothelial carcinoma". Discover Oncology. 15 (1): 622. doi:10.1007/s12672-024-01505-z. ISSN 2730-6011. PMC 11541995. PMID 39503984.
Van Hoogstraten et al. 2023, pp. 291–292. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Van Hoogstraten et al. 2023, pp. 292–293. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Van Hoogstraten et al. 2023, p. 295. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Van Hoogstraten et al. 2023, p. 296. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Mossanen 2021, p. 449. Mossanen M (June 2021). "The Epidemiology of Bladder Cancer". Hematol Oncol Clin North Am. 35 (3): 445–455. doi:10.1016/j.hoc.2021.02.001. PMID 33958144.
Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE (19 January 2022). "Relevance of pRB Loss in Human Malignancies". Clinical Cancer Research. 28 (2): Table 1. doi:10.1158/1078-0432.CCR-21-1565. PMC 9306333. PMID 34407969.
Van Hoogstraten et al. 2023, p. 293. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Teoh et al. 2022, p. 285. Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M (May 2022). "Recurrence mechanisms of non-muscle-invasive bladder cancer – a clinical perspective". Nat Rev Urol. 19 (5): 280–294. doi:10.1038/s41585-022-00578-1. PMID 35361927.
Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M (October 2016). "Female with bladder cancer: what and why is there a difference?". Translational Andrology and Urology. 5 (5): 668–682. doi:10.21037/tau.2016.03.22. PMC 5071204. PMID 27785424.
Mossanen 2021, p. 448. Mossanen M (June 2021). "The Epidemiology of Bladder Cancer". Hematol Oncol Clin North Am. 35 (3): 445–455. doi:10.1016/j.hoc.2021.02.001. PMID 33958144.
Burgess & DeRegis 2019, p. 314–317. Burgess KE, DeRegis CJ (March 2019). "Urologic Oncology". Vet Clin North Am Small Anim Pract. 49 (2): 311–323. doi:10.1016/j.cvsm.2018.11.006. PMID 30635132.
Burgess & DeRegis 2019, p. 314–315. Burgess KE, DeRegis CJ (March 2019). "Urologic Oncology". Vet Clin North Am Small Anim Pract. 49 (2): 311–323. doi:10.1016/j.cvsm.2018.11.006. PMID 30635132.
Iya AM, Beyer K, Kotecha P, Kibaru J, Abdullahi M, Alhassan SU, et al. (March 2022). "Scoping review: bladder cancer in Nigeria – what are the gaps in clinical care and research?". BMJ Open. 12 (3) e049241. doi:10.1136/bmjopen-2021-049241. ISSN 2044-6055. PMC 8905928. PMID 35260447.
Boormans JL, Zwarthoff EC (7 January 2016). "Limited Funds for Bladder Cancer Research and What Can We Do About It". Bladder Cancer. 2 (1): 49–51. doi:10.3233/BLC-150042. ISSN 2352-3727. PMC 4927910. PMID 27376124.

fiercepharma.com (Global: low place; English: 8,341^st place)

"Gilead Pulls Trodelvy's Approval in Bladder Cancer after Trial Flop, FDA Discussions". Fierce Pharma. 18 October 2024. Retrieved 15 November 2024.

fightbladdercancer.co.uk (Global: low place; English: low place)

"Home". Fight Bladder Cancer. Retrieved 12 March 2025.

gettingitrightfirsttime.co.uk (Global: low place; English: low place)

Carter M (19 May 2025). "How-to manual supports urology teams to increase use of transurethral laser ablation (TULA) for bladder cancer". Getting It Right First Time – GIRFT. Retrieved 11 May 2026.

icr.ac.uk (Global: low place; English: low place)

"Personalised radiotherapy for people with bladder cancer shows promise". www.icr.ac.uk. Retrieved 12 March 2025.

nhs.uk (Global: 2,637^th place; English: 2,254^th place)

"Causes – Bladder Cancer". National Health Service. 1 July 2021. Retrieved 16 October 2024.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Lenis, Lec & Chamie 2020, p. 1981. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Ahmadi, Duddalwar & Daneshmand 2021, pp. 532–533. Ahmadi H, Duddalwar V, Daneshmand S (June 2021). "Diagnosis and Staging of Bladder Cancer". Hematol Oncol Clin North Am. 35 (3): 531–541. doi:10.1016/j.hoc.2021.02.004. PMID 33958149.
Lenis, Lec & Chamie 2020, p. 1982. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Lenis, Lec & Chamie 2020, p. 1980. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Ng CP, Light A, Eleftheriou C, Hug O, Richardson E, Gill-Taylor T, et al. (July 2025). "Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study". BJUI Compass. 6 (7) e70052. doi:10.1002/bco2.70052. ISSN 2688-4526. PMC 12270553. PMID 40678112.
Srour MD, Mohamed A, Mathur S (October 2025). "Comparative Efficacy of Transurethral Laser Ablation Versus Conventional Methods in the Management of Recurrent Non-Muscle-Invasive Bladder Tumours". Cureus. 17 (10) e94455. doi:10.7759/cureus.94455. ISSN 2168-8184. PMC 12612793. PMID 41246593.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection-A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection—A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Xu J, Wang C, Ouyang J, Sun J, Hu C (2020). "Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review". Urologia Internationalis. 104 (9–10): 810–823. doi:10.1159/000506655. ISSN 1423-0399. PMID 32460292.
Teoh et al. 2022, p. 280. Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M (May 2022). "Recurrence mechanisms of non-muscle-invasive bladder cancer – a clinical perspective". Nat Rev Urol. 19 (5): 280–294. doi:10.1038/s41585-022-00578-1. PMID 35361927.
Compérat et al. 2022, pp. 1717–1718. Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. (November 2022). "Current best practice for bladder cancer: a narrative review of diagnostics and treatments". Lancet. 400 (10364): 1712–1721. doi:10.1016/S0140-6736(22)01188-6. PMID 36174585.
Lenis, Lec & Chamie 2020, p. 1986. Lenis AT, Lec PM, Chamie K (November 2020). "Bladder Cancer: A Review". JAMA. 324 (19): 1980–1991. Bibcode:2020JAMA..324.1980L. doi:10.1001/jama.2020.17598. PMID 33201207.
Majeed H, Gupta V (14 August 2023). Adverse Effects of Radiation Therapy. StatPearls Publishing LLC. PMID 33085406. NBK563259. Retrieved 24 October 2024.
Huh JW, Tanksley J, Chino J, Willett CG, Dewhirst MW (1 July 2020). "Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators". Clinical Cancer Research. 26 (13): 3079–3090. doi:10.1158/1078-0432.CCR-19-2744. ISSN 1078-0432. PMID 32098770. Retrieved 24 October 2024.
Chen X, Li Y, Huang J, Zhang Q, Tan C, Liu Y, et al. (6 November 2024). "Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in bladder urothelial carcinoma". Discover Oncology. 15 (1): 622. doi:10.1007/s12672-024-01505-z. ISSN 2730-6011. PMC 11541995. PMID 39503984.
Van Hoogstraten et al. 2023, pp. 291–292. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Van Hoogstraten et al. 2023, pp. 292–293. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Van Hoogstraten et al. 2023, p. 295. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Van Hoogstraten et al. 2023, p. 296. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Mossanen 2021, p. 449. Mossanen M (June 2021). "The Epidemiology of Bladder Cancer". Hematol Oncol Clin North Am. 35 (3): 445–455. doi:10.1016/j.hoc.2021.02.001. PMID 33958144.
Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE (19 January 2022). "Relevance of pRB Loss in Human Malignancies". Clinical Cancer Research. 28 (2): Table 1. doi:10.1158/1078-0432.CCR-21-1565. PMC 9306333. PMID 34407969.
Van Hoogstraten et al. 2023, p. 293. Van Hoogstraten LM, Vrieling A, Van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (May 2023). "Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice". Nat Rev Clin Oncol. 20 (5): 287–304. doi:10.1038/s41571-023-00744-3. PMID 36914746.
Teoh et al. 2022, p. 285. Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M (May 2022). "Recurrence mechanisms of non-muscle-invasive bladder cancer – a clinical perspective". Nat Rev Urol. 19 (5): 280–294. doi:10.1038/s41585-022-00578-1. PMID 35361927.
Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M (October 2016). "Female with bladder cancer: what and why is there a difference?". Translational Andrology and Urology. 5 (5): 668–682. doi:10.21037/tau.2016.03.22. PMC 5071204. PMID 27785424.
Mossanen 2021, p. 448. Mossanen M (June 2021). "The Epidemiology of Bladder Cancer". Hematol Oncol Clin North Am. 35 (3): 445–455. doi:10.1016/j.hoc.2021.02.001. PMID 33958144.
Burgess & DeRegis 2019, p. 314–317. Burgess KE, DeRegis CJ (March 2019). "Urologic Oncology". Vet Clin North Am Small Anim Pract. 49 (2): 311–323. doi:10.1016/j.cvsm.2018.11.006. PMID 30635132.
Burgess & DeRegis 2019, p. 314–315. Burgess KE, DeRegis CJ (March 2019). "Urologic Oncology". Vet Clin North Am Small Anim Pract. 49 (2): 311–323. doi:10.1016/j.cvsm.2018.11.006. PMID 30635132.
Iya AM, Beyer K, Kotecha P, Kibaru J, Abdullahi M, Alhassan SU, et al. (March 2022). "Scoping review: bladder cancer in Nigeria – what are the gaps in clinical care and research?". BMJ Open. 12 (3) e049241. doi:10.1136/bmjopen-2021-049241. ISSN 2044-6055. PMC 8905928. PMID 35260447.
Boormans JL, Zwarthoff EC (7 January 2016). "Limited Funds for Bladder Cancer Research and What Can We Do About It". Bladder Cancer. 2 (1): 49–51. doi:10.3233/BLC-150042. ISSN 2352-3727. PMC 4927910. PMID 27376124.

ncbi.nlm.nih.gov

Ng CP, Light A, Eleftheriou C, Hug O, Richardson E, Gill-Taylor T, et al. (July 2025). "Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study". BJUI Compass. 6 (7) e70052. doi:10.1002/bco2.70052. ISSN 2688-4526. PMC 12270553. PMID 40678112.
Srour MD, Mohamed A, Mathur S (October 2025). "Comparative Efficacy of Transurethral Laser Ablation Versus Conventional Methods in the Management of Recurrent Non-Muscle-Invasive Bladder Tumours". Cureus. 17 (10) e94455. doi:10.7759/cureus.94455. ISSN 2168-8184. PMC 12612793. PMID 41246593.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection-A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection—A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Majeed H, Gupta V (14 August 2023). Adverse Effects of Radiation Therapy. StatPearls Publishing LLC. PMID 33085406. NBK563259. Retrieved 24 October 2024.
Chen X, Li Y, Huang J, Zhang Q, Tan C, Liu Y, et al. (6 November 2024). "Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in bladder urothelial carcinoma". Discover Oncology. 15 (1): 622. doi:10.1007/s12672-024-01505-z. ISSN 2730-6011. PMC 11541995. PMID 39503984.
Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE (19 January 2022). "Relevance of pRB Loss in Human Malignancies". Clinical Cancer Research. 28 (2): Table 1. doi:10.1158/1078-0432.CCR-21-1565. PMC 9306333. PMID 34407969.
Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M (October 2016). "Female with bladder cancer: what and why is there a difference?". Translational Andrology and Urology. 5 (5): 668–682. doi:10.21037/tau.2016.03.22. PMC 5071204. PMID 27785424.
Iya AM, Beyer K, Kotecha P, Kibaru J, Abdullahi M, Alhassan SU, et al. (March 2022). "Scoping review: bladder cancer in Nigeria – what are the gaps in clinical care and research?". BMJ Open. 12 (3) e049241. doi:10.1136/bmjopen-2021-049241. ISSN 2044-6055. PMC 8905928. PMID 35260447.
Boormans JL, Zwarthoff EC (7 January 2016). "Limited Funds for Bladder Cancer Research and What Can We Do About It". Bladder Cancer. 2 (1): 49–51. doi:10.3233/BLC-150042. ISSN 2352-3727. PMC 4927910. PMID 27376124.

web.archive.org (Global: 1^st place; English: 1^st place)

"WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 11 November 2009. Retrieved 11 November 2009.

who.int (Global: 213^th place; English: 314^th place)

"WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 11 November 2009. Retrieved 11 November 2009.

worldbladdercancer.org (Global: low place; English: low place)

"Home". World Bladder Cancer Patient Coalition. Retrieved 12 March 2025.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Ng CP, Light A, Eleftheriou C, Hug O, Richardson E, Gill-Taylor T, et al. (July 2025). "Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study". BJUI Compass. 6 (7) e70052. doi:10.1002/bco2.70052. ISSN 2688-4526. PMC 12270553. PMID 40678112.
Srour MD, Mohamed A, Mathur S (October 2025). "Comparative Efficacy of Transurethral Laser Ablation Versus Conventional Methods in the Management of Recurrent Non-Muscle-Invasive Bladder Tumours". Cureus. 17 (10) e94455. doi:10.7759/cureus.94455. ISSN 2168-8184. PMC 12612793. PMID 41246593.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection-A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Deacon NN, Nielsen NK, Jensen JB (24 April 2024). "Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection—A Prospective Study". Cancers. 16 (9): 1630. doi:10.3390/cancers16091630. ISSN 2072-6694. PMC 11083450. PMID 38730582.
Xu J, Wang C, Ouyang J, Sun J, Hu C (2020). "Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review". Urologia Internationalis. 104 (9–10): 810–823. doi:10.1159/000506655. ISSN 1423-0399. PMID 32460292.
Huh JW, Tanksley J, Chino J, Willett CG, Dewhirst MW (1 July 2020). "Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators". Clinical Cancer Research. 26 (13): 3079–3090. doi:10.1158/1078-0432.CCR-19-2744. ISSN 1078-0432. PMID 32098770. Retrieved 24 October 2024.
Chen X, Li Y, Huang J, Zhang Q, Tan C, Liu Y, et al. (6 November 2024). "Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in bladder urothelial carcinoma". Discover Oncology. 15 (1): 622. doi:10.1007/s12672-024-01505-z. ISSN 2730-6011. PMC 11541995. PMID 39503984.
Iya AM, Beyer K, Kotecha P, Kibaru J, Abdullahi M, Alhassan SU, et al. (March 2022). "Scoping review: bladder cancer in Nigeria – what are the gaps in clinical care and research?". BMJ Open. 12 (3) e049241. doi:10.1136/bmjopen-2021-049241. ISSN 2044-6055. PMC 8905928. PMID 35260447.
Boormans JL, Zwarthoff EC (7 January 2016). "Limited Funds for Bladder Cancer Research and What Can We Do About It". Bladder Cancer. 2 (1): 49–51. doi:10.3233/BLC-150042. ISSN 2352-3727. PMC 4927910. PMID 27376124.

Bladder cancer (English Wikipedia)

aacrjournals.org (Global: 9,401st place; English: 9,586th place)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

aicr.org (Global: low place; English: low place)

appliedradiationoncology.com (Global: low place; English: low place)

bcan.org (Global: low place; English: low place)

cancer.gov (Global: 1,906th place; English: 1,649th place)

cancer.org (Global: 4,631st place; English: 3,828th place)

cancerresearchuk.org (Global: 9,972nd place; English: 7,596th place)

doi.org (Global: 2nd place; English: 2nd place)

fiercepharma.com (Global: low place; English: 8,341st place)

fightbladdercancer.co.uk (Global: low place; English: low place)

gettingitrightfirsttime.co.uk (Global: low place; English: low place)

icr.ac.uk (Global: low place; English: low place)

nhs.uk (Global: 2,637th place; English: 2,254th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

web.archive.org (Global: 1st place; English: 1st place)

who.int (Global: 213th place; English: 314th place)

worldbladdercancer.org (Global: low place; English: low place)

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

aacrjournals.org (Global: 9,401^st place; English: 9,586^th place)

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

cancer.gov (Global: 1,906^th place; English: 1,649^th place)

cancer.org (Global: 4,631^st place; English: 3,828^th place)

cancerresearchuk.org (Global: 9,972^nd place; English: 7,596^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

fiercepharma.com (Global: low place; English: 8,341^st place)

nhs.uk (Global: 2,637^th place; English: 2,254^th place)

nih.gov (Global: 5^th place; English: 5^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

who.int (Global: 213^th place; English: 314^th place)

worldcat.org (Global: 4^th place; English: 4^th place)